Wadim Bowl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wadim Bowl has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ebrahimifard
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications - Behrooz Hooshyar Yousefi
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications - Friederike Eilsberger
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications - Markus Luster
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications - Pietro Di Fazio
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications - Shamim Bagheri
Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, 35043 Marburg, Germany
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 9032
Levothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors
Background/Objectives: In thyroid cancer, high levothyroxine (LT4) doses may reflect intentional thyroid-stimulating hormone (TSH) suppression rather than impaired bioavailability. We assessed gastrointestinal and medication-related factors in relation to LT4 dose after accounting for treatment goals and body mass index (BMI). Methods: This cross-sectional study included 218 LT4-treated patients and 69 non-LT4 reference patients. A structured questionnaire captured gastrointestinal symptoms, comorbidities, medications, and administration timing. BMI was calculated from recorded height and weight. The main adjusted analysis was restricted to participants with clinician-assessed target achievement; exploratory models additionally used measured TSH categories. Multivariable models used HC3 robust standard errors. Results: Among LT4-treated patients, 201 (92.2%) had thyroid cancer, 81 (37.2%) reported gastrointestinal symptoms, 74 (33.9%) had at least one potential interfering factor, and 49 (22.5%) reported proton-pump inhibitor (PPI) use. Factor prevalence was comparable in the reference population after adjustment for age, sex, and BMI. In the BMI-adjusted model (n = 156), PPI use was not associated with higher LT4 dose (β = −0.031 µg/kg/day, 95% CI −0.193 to 0.131; p = 0.703). Intended TSH suppression was associated with higher dose (β = 0.420, 95% CI 0.269–0.570; p < 0.001), whereas BMI was inversely associated with dose per kilogram. An exploratory BMI-adjusted model accounting for measured TSH categories also showed no significant association with PPI exposure (n = 184, β = 0.024 µg/kg/day, 95% CI −0.122 to 0.169; p = 0.751). Conclusions: Potentially interfering factors were common but were not independently associated with higher dose requirements. LT4 dose in thyroid cancer should be interpreted in relation to therapeutic intent and anthropometry; PPI exposure alone was not a reliable marker of increased dose requirement.
- 18 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 9032
Open AccessLevothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors
Background/Objectives: In thyroid cancer, high levothyroxine (LT4) doses may reflect intentional thyroid-stimulating hormone (TSH) suppression rather than impaired bioavailability. We assessed gastrointestinal and medication-related factors in relation to LT4 dose after accounting for treatment goals and body mass index (BMI). Methods: This cross-sectional study included 218 LT4-treated patients and 69 non-LT4 reference patients. A structured questionnaire captured gastrointestinal symptoms, comorbidities, medications, and administration timing. BMI was calculated from recorded height and weight. The main adjusted analysis was restricted to participants with clinician-assessed target achievement; exploratory models additionally used measured TSH categories. Multivariable models used HC3 robust standard errors. Results: Among LT4-treated patients, 201 (92.2%) had thyroid cancer, 81 (37.2%) reported gastrointestinal symptoms, 74 (33.9%) had at least one potential interfering factor, and 49 (22.5%) reported proton-pump inhibitor (PPI) use. Factor prevalence was comparable in the reference population after adjustment for age, sex, and BMI. In the BMI-adjusted model (n = 156), PPI use was not associated with higher LT4 dose (β = −0.031 µg/kg/day, 95% CI −0.193 to 0.131; p = 0.703). Intended TSH suppression was associated with higher dose (β = 0.420, 95% CI 0.269–0.570; p < 0.001), whereas BMI was inversely associated with dose per kilogram. An exploratory BMI-adjusted model accounting for measured TSH categories also showed no significant association with PPI exposure (n = 184, β = 0.024 µg/kg/day, 95% CI −0.122 to 0.169; p = 0.751). Conclusions: Potentially interfering factors were common but were not independently associated with higher dose requirements. LT4 dose in thyroid cancer should be interpreted in relation to therapeutic intent and anthropometry; PPI exposure alone was not a reliable marker of increased dose requirement.
- Open Access
Therapeutic Consequences of 68Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D’Amico-Defined Risk Groups
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.
Open AccessTherapeutic Consequences of 68Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D’Amico-Defined Risk Groups
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.